Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32671601
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Cardiovasc+Drugs+Ther
2021 ; 35
(2
): 249-259
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
#MMPMID32671601
Talasaz AH
; Kakavand H
; Van Tassell B
; Aghakouchakzadeh M
; Sadeghipour P
; Dunn S
; Geraiely B
Cardiovasc Drugs Ther
2021[Apr]; 35
(2
): 249-259
PMID32671601
show ga
Coronavirus disease of 2019 (COVID-19), which is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world
over. The disease was declared "pandemic" by the World Health Organization. An
approved therapy for patients with COVID-19 has yet to emerge; however, there are
some medications used in the treatment of SARS-CoV-2 infection globally including
hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and
anti-inflammatory agents. Patients with underlying cardiovascular disease are at
increased risk of mortality and morbidity from COVID-19. Moreover, patients with
chronic stable states and even otherwise healthy individuals might sustain acute
cardiovascular problems due to COVID-19 infection. This article seeks to review
the latest evidence with a view to explaining possible pharmacotherapies for the
cardiovascular complications of COVID-19 including acute coronary syndrome, heart
failure, myocarditis, arrhythmias, and venous thromboembolism, as well as
possible interactions between these medications and those currently administered
(or under evaluation) in the treatment of COVID-19.